Summary of 康辰药业 Conference Call Company Overview - 康辰药业 is a Chinese innovative pharmaceutical company focused on research, production, and sales, emphasizing clinical value in new drug development [3][4]. Key Points Industry Dynamics - The pharmaceutical industry in China has undergone significant changes over the past decade, presenting both challenges and opportunities [3]. - The principle of "product is king" remains a constant in the evolving industry landscape [3]. Strategic Planning - 康辰药业 launched a new ten-year strategic plan from 2023 to 2032, focusing on product pipeline restructuring and innovation [4]. - The company is enhancing its organizational structure and talent management to support its strategic goals [5]. Financial Performance - In 2023, 康辰药业 achieved a revenue of 9.2 billion yuan, a year-on-year increase of 6.15% [16]. - The net profit attributable to the parent company was 1.5 billion yuan, up 48.2% year-on-year [17]. - For Q1 2024, the company reported a revenue of 1.99 billion yuan, a growth of 20.67% compared to the previous year [21]. Product Development - The company is advancing its innovative drug projects, including KC1086, which has been officially launched and is seen as a significant milestone in its R&D capabilities [7]. - The clinical research for KC1036 and Jin Cao Pian (金草片) is progressing well, with KC1036 showing promising results in clinical trials for esophageal cancer [28][30]. Marketing and Sales Strategy - 康辰药业 is transforming its marketing model to include a combination of alliance and self-operated teams, focusing on digital management [6]. - The company capitalized on favorable policies regarding medical insurance to enhance drug accessibility and market presence [13]. Governance and Compliance - The company has strengthened its governance structure and compliance measures, ensuring adherence to regulations and enhancing operational efficiency [9][37]. - 康辰药业 maintains a commitment to transparency and investor communication, aiming to protect shareholder interests [38]. Cultural Development - 康辰药业's corporate culture has evolved through various stages, with a recent focus on embedding a culture of execution and accountability within its organizational framework [36]. Future Outlook - The company is poised to continue its growth trajectory by leveraging its innovative capabilities and adapting to market changes, with a strong emphasis on talent and product pipeline development [18][20]. Additional Insights - The company has implemented a robust incentive system to enhance employee engagement and performance [5]. - 康辰药业's commitment to R&D is reflected in its significant investment, with R&D expenses accounting for 19.18% of its revenue [25]. This summary encapsulates the key aspects of 康辰药业's conference call, highlighting its strategic direction, financial performance, product development, and commitment to governance and compliance.

证券代码：603590 证券简称：康辰药业 公告编号：临 2024-027 北京康辰药业股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络文字互动 投资者可于 2024 年 06 月 19 日(星期三) 至 06 月 25 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@konruns.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京康辰药业股份有限公司（以下简称"公司"）已于 2024 年 4 月 26 日发布公司 2023 年度报告和 2024 年一季度报告，为便于广大投资者更全面 深入地了解公司 2023 年度报告和 2024 年一季度经营成果、财务状况，公司 计划于 2024 年 06 月 26 日下午 15:00-16:30 举行 2023 年度暨 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2024-026 北京康辰药业股份有限公司 关于获得第八批国家级制造业单项冠军企业认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 根据《关于加快培育发展制造业优质企业的指导意见》（工信部政法〔2021〕 70 号）、《工业和信息化部办公厅关于开展 2023 年制造业单项冠军企业遴选认定 和复核评价工作的通知》（工信厅政法函〔2023〕263 号）等规定，经北京康辰 药业股份有限公司（以下简称"公司"）申报、北京市工业经济联合会形式审查、 北京市经济和信息化局核查推荐、工业和信息化部组织中国工业经济联合会等第 三方机构核查论证及社会公示等程序，公司凭借尖吻蝮蛇血凝酶（商品名："苏 灵"，下称"苏灵"）产品的技术优势及市场地位被认定为工业和信息化部第八批 国家级制造业单项冠军企业，并于近日获得由工业和信息化部、中国工业经济联 合会联合颁发的证书。 二、对公司的影响 制造业单项冠军企业是指长期专注于制造业特定细分领域，生产技术或工艺 水平国际先进，单 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京康辰药业股份有限公司 国枫律股字[2024]A0229 号 致：北京康辰药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2023 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《北京康辰药业股份有限公司章程》（以下简称"《公 司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席会议人 员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特 ...

证券代码：603590 证券简称：康辰药业 公告编号：2024-025 北京康辰药业股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集并发布公告通知，由公司董事长刘建华先生 主持，会议表决方式为现场和网络投票相结合，本次大会的召集与召开程序、出 席会议人员资格及表决程序符合《公司法》及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事 9 人，出席 9 人； 2、公司在任监事 3 人，出席 3 人； 3、公司董事会秘书兼财务总监孙玉萍女士出席了本次会议。 本次会议是否有否决议案：有 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 11 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | | | | 63,662,060 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 ...

北京康辰药业股份有限公司 2023 年年度股东大会 会议资料 二〇二四年五月 1 | 2023 | 年年度股东大会会议议程 | 3 | | --- | --- | --- | | 2023 | 年年度股东大会会议须知 | 5 | | 2023 | 年年度股东大会会议议案 | 6 | 北京康辰药业股份有限公司 2023 年年度股东大会会议议程 一、会议时间： 现场会议召开时间：2024 年 5 月 16 日上午 11:00 网络投票起止时间：自 2024 年 5 月 16 日至 2024 年 5 月 16 日。采用上海证 券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日 的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的 投票时间为股东大会召开当日的 9:15-15:00。 二、会议地点：北京市昌平区中关村生命科学园科学园路 7 号院 3 号楼公司第三 会议室 4 （五）股东发言、提问 （六）与会股东（或授权代表）现场投票表决 （七）计票人、监票人统计现场投票结果 （八）休会，汇总网络投票与现场投票表决结果 （九）主持人宣读股东大会表决 ...

Financial Performance - The company's operating revenue for 2023 reached ¥920,011,779.75, representing a 6.15% increase compared to ¥866,725,922.18 in 2022[24]. - Net profit attributable to shareholders was ¥150,450,744.29, a significant increase of 48.24% from ¥101,490,338.51 in the previous year[24]. - The net cash flow from operating activities increased by 66.56% to ¥199,353,548.33, up from ¥119,690,343.34 in 2022[24]. - Basic earnings per share rose to ¥0.96, reflecting a 47.69% increase from ¥0.65 in 2022[25]. - Total assets at the end of 2023 were ¥3,780,818,095.19, marking a 10.40% increase from ¥3,424,800,761.83 at the end of 2022[24]. - The net assets attributable to shareholders increased by 4.58% to ¥3,059,941,948.61 from ¥2,925,907,946.04 in 2022[24]. - The company reported a quarterly revenue of ¥285,729,671.01 in Q2 2023, which was the highest among the four quarters[28]. - The company achieved a revenue of 920.01 million CNY, representing a year-on-year growth of 6.15%[37]. - The net profit attributable to the parent company was 150.45 million CNY, an increase of 48.24% compared to the previous year[37]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 126.94 million CNY, up 42.51% year-on-year[37]. Research and Development - The company invested a total of 176.47 million CNY in R&D throughout 2023, supporting the development of innovative drug projects[40]. - The company has established a four-tier talent team structure to enhance its original drug development capabilities[41]. - The company is focusing on unmet clinical needs in areas such as hemostasis, bone metabolism, and oncology for its R&D efforts[44]. - The company has formed partnerships with numerous research institutions and hospitals to enhance its R&D efficiency and quality[45]. - The company is committed to a dual-driven R&D strategy of "self-research + external introduction" to accelerate its innovative drug pipeline[40]. - The company is actively conducting a Phase III clinical trial for KC1036, targeting advanced esophageal squamous cell carcinoma[84]. - The company has a total of 8 major R&D projects, with varying stages from clinical trials to preclinical research[140]. - The company is currently conducting clinical trials for multiple products, including KC1036 and ZY5301, which are in Phase III and have significant market potential[141][148]. Market and Product Development - The sales volume of the drug "Su Ling" increased by 19.83% during the reporting period[38]. - The company achieved a sales target for "Sulingen" in 2023, expanding its market share and solidifying its leading position in the market[48]. - The company is focusing on transforming its marketing management model, establishing a digital self-operated system to enhance marketing capabilities for 2024[48]. - The company has a significant market potential in the perioperative hemostatic drug market, with an estimated surgical volume growth of approximately 9% in 2023, reaching over 80 million cases[56]. - The company is positioned in the pharmaceutical manufacturing industry, focusing on hemostatic, tumor/immunity, and bone metabolism fields[53]. - The company is committed to innovation and quality development, aiming to become a leading international pharmaceutical brand while focusing on high-quality product lines[64]. - The company aims to enhance its market share for its leading hemostatic product "Su Ling" by leveraging its differentiated advantages and expanding its sales network[166]. Compliance and Governance - The company emphasizes the importance of ensuring the authenticity, accuracy, and completeness of the annual report[4]. - The board of directors and supervisory board members have all attended the board meeting[4]. - The company has no record of penalties from securities regulatory agencies in the past three years[191]. - The company is committed to monitoring changes in national pharmaceutical policies to turn challenges into opportunities[172]. - The company is enhancing its quality management system to ensure no quality defects across all production stages[173]. - The company has established a dynamic adjustment mechanism for its medical insurance catalog in response to policy changes[172]. - The company is actively engaging in investor relations to improve governance and transparency[175]. Strategic Initiatives - The company plans to distribute a cash dividend of RMB 3.00 per 10 shares to all shareholders, subject to approval at the shareholders' meeting[6]. - The company plans to continue expanding its market presence and is focusing on new product development and technological advancements[181]. - The company aims to strengthen its position in the pharmaceutical industry through strategic investments and acquisitions[156]. - The company is pursuing strategic collaborations to accelerate the layout of its innovative drug pipeline[86]. - The company will continue to invest in research and development, focusing on innovative drug development across various fields, particularly in oncology and hemostatic agents[164]. Risk Management - The company has outlined various risk factors that may affect its future development strategies and operational goals[10]. - The company is focusing on risk management and process control for new product development to enhance operational quality[173]. - The pharmaceutical industry is facing strong regulatory policies that could impact the company's operations if not addressed timely[172]. Shareholder and Management Information - Liu Jianhua, the chairman, holds 58,466,760 shares, making him the largest shareholder, with a total compensation of 60.49 million yuan for the reporting period[180]. - The total compensation for all directors and senior management during the reporting period amounted to 821.58 million yuan[182]. - The company has maintained a stable leadership structure, with key executives serving multiple terms, ensuring continuity in management[183]. - The company has revised its stock incentive plan, which was approved at the shareholders' meeting held on August 16, 2023[178].

Financial Performance - The company's operating revenue for 2023 was ¥920,011,779.75, representing a 6.15% increase from ¥866,725,922.18 in 2022 [24]. - Net profit attributable to shareholders for 2023 reached ¥150,450,744.29, a significant increase of 48.24% compared to ¥101,490,338.51 in 2022 [24]. - The net cash flow from operating activities for 2023 was ¥199,353,548.33, marking a 66.56% increase from ¥119,690,343.34 in 2022 [24]. - Basic earnings per share for 2023 were ¥0.96, up 47.69% from ¥0.65 in 2022 [25]. - The weighted average return on equity increased to 5.03% in 2023, up from 3.49% in 2022, an increase of 1.54 percentage points [25]. - Total assets at the end of 2023 were ¥3,780,818,095.19, a 10.40% increase from ¥3,424,800,761.83 at the end of 2022 [24]. - The net profit after deducting non-recurring gains and losses for 2023 was ¥126,935,433.82, a 42.51% increase from ¥89,072,883.45 in 2022 [24]. - The company reported a net profit of ¥1,817,228.26 in Q4 2023, a significant decrease compared to previous quarters [28]. Research and Development - The company invested a total of 176.47 million CNY in R&D throughout 2023, supporting the development of innovative drug projects [40]. - The company has established a four-tier talent team structure to enhance its original drug development capabilities [41]. - The company is focusing on unmet clinical needs in areas such as hemostasis, perioperative care, bone metabolism, and oncology for its R&D efforts [44]. - The company has formed partnerships with numerous research institutions and hospitals to enhance its R&D efficiency and quality [45]. - The company is committed to a dual-driven R&D strategy of "self-research + external introduction" to accelerate its innovative drug pipeline [40]. - The company is currently conducting clinical trials for multiple products, including KC1036 and ZY5301, which are in Phase III and have shown promising results [141][148]. - The company has a total of 8 major R&D projects, with varying stages of development, including clinical trials and preclinical research [140]. Market and Product Development - The company is focusing on expanding its market presence and enhancing product development strategies in response to changing market dynamics [93]. - The company aims to enhance its market share for its product "Su Ling" by leveraging its differentiated advantages in medical insurance and expanding its presence in the coagulation enzyme market [166]. - The company plans to accelerate the clinical and market progress of its in-development products, focusing on key projects such as KC1036 and the registration of "Jincao Pian" and canine injection products [168]. - The company is committed to expanding its product pipeline in hemostatic drugs, enhancing its competitive advantage in the coagulation drug field [133]. Corporate Governance and Management - The company has a strategy to ensure that the remuneration of directors and senior management is competitive externally and balanced internally [188]. - The board of directors approved the 2023 restricted stock incentive plan, which aims to align the interests of management and shareholders [178]. - The company has appointed new directors and management, including Jin Li, who joined the board in January 2023, indicating a strategic refresh [183]. - The company has a comprehensive remuneration decision-making process involving the board of directors and shareholders [187]. - The company has no rejected proposals during the shareholders' meeting, indicating strong support for its strategic direction [178]. Regulatory and Market Environment - The pharmaceutical industry is undergoing significant regulatory changes, impacting procurement, medical insurance, and overall industry dynamics [160]. - The Chinese pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 9.6%, reaching RMB 228.73 billion by 2025 and RMB 299.11 billion by 2030 [162]. - The ongoing medical anti-corruption efforts are expected to enhance transparency and credibility in the pharmaceutical industry, benefiting companies that rely on innovation and high-quality products [61]. Risk Management - The company has detailed various risk factors that may affect its future development strategies and operational goals [10]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties [8]. - There are no violations of decision-making procedures regarding external guarantees [8]. - The company is actively monitoring changes in national pharmaceutical policies to adapt and turn challenges into opportunities for development [172]. Shareholder Engagement - The company plans to distribute a cash dividend of RMB 3.00 per 10 shares to all shareholders, subject to the approval of the shareholders' meeting [6]. - The company reported a total of 75,577,800 shares held by directors and senior management at the end of the reporting period, an increase of 570,000 shares compared to the beginning of the year [182]. - Liu Jianhua, the chairman, holds 58,466,760 shares, making him the largest shareholder, with a total compensation of 60.49 million yuan for the reporting period [180].

Financial Performance - The company's operating revenue for 2023 reached ¥920,011,779.75, representing a 6.15% increase compared to ¥866,725,922.18 in 2022 [24]. - Net profit attributable to shareholders was ¥150,450,744.29, a significant increase of 48.24% from ¥101,490,338.51 in the previous year [24]. - The net cash flow from operating activities increased by 66.56% to ¥199,353,548.33, up from ¥119,690,343.34 in 2022 [24]. - Basic earnings per share rose to ¥0.96, reflecting a 47.69% increase from ¥0.65 in 2022 [25]. - The weighted average return on equity improved to 5.03%, an increase of 1.54 percentage points from 3.49% in 2022 [25]. - Total assets at the end of 2023 were ¥3,780,818,095.19, a 10.40% increase from ¥3,424,800,761.83 at the end of 2022 [24]. - The company reported a quarterly revenue of ¥285,729,671.01 in Q2 2023, which was the highest among the four quarters [28]. - The net profit attributable to shareholders in Q3 2023 was ¥55,744,481.89, showing a strong performance compared to Q1 and Q4 [28]. - The net profit attributable to the parent company was 150.45 million CNY, an increase of 48.24% compared to the previous year [37]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 126.94 million yuan, up 42.51% year-on-year [81]. Research and Development - The company invested a total of 176.47 million CNY in R&D throughout 2023, supporting the development of innovative drug projects [40]. - The company has established a four-tier talent team structure to enhance its original drug development capabilities [41]. - The company is focusing on unmet clinical needs in areas such as hemostasis, bone metabolism, and oncology for its R&D innovations [44]. - The company has formed partnerships with numerous research institutions and hospitals to enhance its R&D efficiency and quality [45]. - The company has made significant progress in its innovative drug development pipeline, including the formal establishment of the project KC1086 [40]. - The company aims to transform its innovative drugs from "China New" to "Global New," reshaping its goals and operational processes [40]. - The R&D personnel count reached 80, accounting for 27% of the total workforce, with 96% holding a bachelor's degree or higher [83]. - The company is conducting a Phase III clinical trial for KC1036, targeting unmet clinical needs in advanced esophageal squamous cell carcinoma [84]. - The company has a total of 8 major R&D projects, with varying stages from clinical trials to preclinical research [140]. - The company has not canceled any major R&D projects during the reporting period, indicating a stable pipeline [143]. Market and Product Development - The sales volume of the drug "Su Ling" increased by 19.83% year-on-year, benefiting from the renewal of medical insurance negotiations [38]. - The company achieved its sales target for "Sulingen" by expanding market share and activating low-activity terminals, benefiting from the removal of medical insurance payment restrictions [48]. - The company is focusing on developing differentiated oncology drugs to enhance clinical value and competitive advantages in a highly concentrated market [171]. - The company aims to enhance its market share for its product "Su Ling" by leveraging its differentiated advantages in the coagulation enzyme market and expanding its sales network [166]. - The company plans to accelerate the clinical and market progress of its in-development products, focusing on key projects such as KC1036 and "Jincao Pian" registration [168]. Governance and Management - The company has confirmed that all board members are present and responsible for the accuracy and completeness of the annual report [4]. - The company has not faced any issues with a majority of directors being unable to guarantee the authenticity of the annual report [9]. - The company appointed Niu Zhanqi as the new president on July 20, 2023, with a stock grant of 350,000 shares during the reporting period [180]. - The company has established a compensation committee to review and recommend remuneration for senior management based on performance assessments [187]. - The company emphasizes the need for competitive and balanced remuneration for its directors and senior management based on industry standards and company performance [188]. - The company has a total of 8 directors and supervisors, with remuneration linked to performance and responsibilities [188]. - The company has maintained a consistent attendance record at board meetings, with no directors missing consecutive meetings [193]. Risk Management and Compliance - The company has outlined various risk factors that may affect its future development strategies and operational goals [10]. - The report emphasizes the importance of investment risk awareness regarding future plans and strategic developments [7]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [8]. - There are no violations of decision-making procedures regarding external guarantees [8]. - The company has not faced any penalties from securities regulatory authorities in the past three years [191]. Market Trends and Opportunities - The Chinese pharmaceutical market is expected to grow steadily, with a projected 9% increase in surgical volume in 2023, indicating significant market potential for hemostatic drugs [56]. - The aging population in China, with 12.4% suffering from osteoporosis, presents a growing market for osteoporosis treatments [57]. - The prevalence of osteoporosis in individuals over 50 years old in China is 32.1% for women and 6% for men, indicating a significant public health issue with a large market potential for osteoporosis treatment drugs [58]. - The company’s product "Su Ling" is the only national class I new drug in the blood coagulation enzyme market, demonstrating significant clinical efficacy, safety, and economic value, with a strong competitive advantage [62][65]. - The company is actively involved in the pharmaceutical industry, which is influenced by new policies promoting the coordinated development of medical insurance, healthcare, and pharmaceuticals [160].

证券代码：603590 证券简称：康辰药业 公告编号：临 2024-015 北京康辰药业股份有限公司 第四届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京康辰药业股份有限公司（以下简称"公司"）第四届董事会第八次会议 通知于 2024 年 4 月 15 日以电子邮件方式发出，会议于 2024 年 4 月 25 日 10:00 在北京市昌平区中关村生命科学园科学园路7号院3号楼公司第三会议室以现场 与通讯表决相结合的方式召开。本次会议由公司董事长刘建华先生主持，应出席 董事 9 名，实际出席董事 9 名。公司监事及高级管理人员列席本次会议。本次会 议的参与表决人数及召开程序符合《公司法》和《公司章程》的有关规定，合法 有效。 二、董事会会议审议情况 1、审议通过《关于 2023 年年度报告及摘要的议案》 具体内容详见公司同日于指定信息披露媒体披露的《北京康辰药业股份有限 公司 2023 年年度报告》和《北京康辰药业股份有限公司 2023 年年度报告摘要》。 表决结果：9 票 ...